
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Dement Geriatr Cogn Dis Extra</journal-id><journal-id journal-id-type="iso-abbrev">Dement Geriatr Cogn Dis Extra</journal-id><journal-id journal-id-type="publisher-id">DEE</journal-id><journal-title-group><journal-title>Dementia and Geriatric Cognitive Disorders EXTRA</journal-title></journal-title-group><issn pub-type="ppub">1664-5464</issn><issn pub-type="epub">1664-5464</issn><publisher><publisher-name>S. Karger AG</publisher-name><publisher-loc>Allschwilerstrasse 10, P.O. Box &#x000b7; Postfach &#x000b7; Case postale, CH&#x02013;4009, Basel, Switzerland &#x000b7; Schweiz &#x000b7; Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.ch</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25873931</article-id><article-id pub-id-type="pmc">4386115</article-id><article-id pub-id-type="doi">10.1159/000375295</article-id><article-id pub-id-type="publisher-id">dee-0005-0096</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title>Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pakdaman</surname><given-names>Hossein</given-names></name><xref ref-type="aff" rid="aff1">a</xref></contrib><contrib contrib-type="author"><name><surname>Harandi</surname><given-names>Ali Amini</given-names></name><xref ref-type="aff" rid="aff1">a</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Hatamian</surname><given-names>Hamidreza</given-names></name><xref ref-type="aff" rid="aff3">c</xref></contrib><contrib contrib-type="author"><name><surname>Tabatabae</surname><given-names>Mojgan</given-names></name><xref ref-type="aff" rid="aff2">b</xref></contrib><contrib contrib-type="author"><name><surname>Delavar Kasmaei</surname><given-names>Hosein</given-names></name><xref ref-type="aff" rid="aff1">a</xref></contrib><contrib contrib-type="author"><name><surname>Ghassemi</surname><given-names>Amirhossein</given-names></name><xref ref-type="aff" rid="aff4">d</xref></contrib><contrib contrib-type="author"><name><surname>Gharagozli</surname><given-names>Koroush</given-names></name><xref ref-type="aff" rid="aff1">a</xref></contrib><contrib contrib-type="author"><name><surname>Ashrafi</surname><given-names>Farzad</given-names></name><xref ref-type="aff" rid="aff1">a</xref></contrib><contrib contrib-type="author"><name><surname>Emami Naeini</surname><given-names>Pardis</given-names></name><xref ref-type="aff" rid="aff5">e</xref></contrib><contrib contrib-type="author"><name><surname>Tavakolian</surname><given-names>Mehrnaz</given-names></name><xref ref-type="aff" rid="aff1">a</xref></contrib><contrib contrib-type="author"><name><surname>Shahin</surname><given-names>Darush</given-names></name><xref ref-type="aff" rid="aff1">a</xref></contrib></contrib-group><aff id="aff1"><sup>a</sup>Department of Neurology, Shahid Beheshti University of Medical Sciences, Iran</aff><aff id="aff2"><sup>b</sup>Social Security, Tehran, Rasht University of Medical Sciences, Rasht, Iran</aff><aff id="aff3"><sup>c</sup>Department of Neurology, Rasht University of Medical Sciences, Rasht, Iran</aff><aff id="aff4"><sup>d</sup>Social Security, Kerman, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff5"><sup>e</sup>School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran</aff><author-notes><corresp id="cor1">*Ali Amini Harandi, MD, Department of Neurology, Shahid Beheshti University of Medical Sciences, Velenjak Street, Shahid Chamran Highway, Tehran 4739 (Iran), E-Mail <email>amini_alli@yahoo.com</email></corresp></author-notes><pub-date pub-type="collection"><season>Jan-Apr</season><year>2015</year></pub-date><pub-date pub-type="epub"><day>7</day><month>3</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>3</month><year>2015</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>5</volume><issue>1</issue><fpage>96</fpage><lpage>106</lpage><permissions><copyright-statement>Copyright &#x000a9; 2015 by S. Karger AG, Basel</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.</license-p></license></permissions><abstract><sec><title>Background</title><p>MLC601 is a possible modulator of amyloid precursor protein processing, and in a clinical trial study MLC601 showed some effectiveness in cognitive function in Alzheimer's disease (AD) patients. We aimed to evaluate the effectiveness and safety of MLC601 in the treatment of mild to moderate AD as compared to 3 approved cholinesterase inhibitors (ChEIs) including donepezil, rivastigmine and galantamine.</p></sec><sec><title>Methods</title><p>In a multicenter, nonblinded, randomized controlled trial, 264 volunteers with AD were randomly divided into 4 groups of 66; groups 1, 2, 3 and 4 received donepezil, rivastigmine, MLC601 and galantamine, respectively. Subjects underwent a clinical diagnostic interview and a cognitive/functional battery including the Mini-Mental State Examination (MMSE) and Alzheimer's Disease Assessment Scale &#x02013; Cognitive subscale (ADAS-Cog). Patients were visited every 4 months, and the score of cognition was recorded by the neurologists.</p></sec><sec><title>Results</title><p>There were no significant differences in age, sex, marital status and baseline score of cognition among the 4 groups. In total, 39 patients (14.7%) left the study. Trend of cognition changes based on the modifications over the time for MMSE and ADAS-cog scores did not differ significantly among groups (p = 0.92 for MMSE and p = 0.87 for ADAS-Cog).</p></sec><sec><title>Conclusion</title><p>MLC601 showed a promising safety profile and also efficacy compared to 3 FDA-approved ChEIs.</p></sec></abstract><kwd-group><title>Key Words</title><kwd>Cholinesterase inhibitor</kwd><kwd>Alzheimer's disease</kwd><kwd>Donepezil</kwd><kwd>Rivastigmine</kwd><kwd>Galantamine</kwd><kwd>MLC601</kwd><kwd>Safety</kwd><kwd>Efficacy</kwd></kwd-group><counts><fig-count count="3"/><table-count count="7"/><ref-count count="46"/><page-count count="11"/></counts></article-meta></front><body><sec sec-type="intro" id="sec1_1"><title>Introduction</title><p>Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by cognitive deterioration together with behavioral disturbances and declining activities of daily living [<xref rid="B1" ref-type="bibr">1</xref>]. It is the leading cause of dementia, accounting for nearly 70% of dementia cases worldwide [<xref rid="B2" ref-type="bibr">2</xref>]. In the recent decade, the prevalence of dementia increased as the proportion of the elderly population expanded. The number of subjects with dementia has been doubling every 20 years and will reach 81.1 million by 2040 [<xref rid="B3" ref-type="bibr">3</xref>]. Although significant progress has been made in both understanding some of the mechanisms of AD pathology and developing therapeutic agents, these efforts have had no impact on decreasing disease prevalence and have had limited effects on improving the clinical course of AD [<xref rid="B4" ref-type="bibr">4</xref>].</p><p>Since 1993, five drugs have been marketed for the treatment of AD. Its current treatment includes cholinesterase inhibitors (ChEIs) [<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>], and N-methyl-D-aspartate receptor blockers [<xref rid="B8" ref-type="bibr">8</xref>]. In spite of enormous research efforts, these treatments are sometimes regarded as having only &#x02018;symptomatic&#x02019; rather than &#x02018;disease-modifying&#x02019; effects, although the utility of this distinction has been questioned [<xref rid="B9" ref-type="bibr">9</xref>]. In other words, current medications cannot cure AD but may help lessen or stabilize signs and symptoms of AD for a limited time. In spite of enormous research efforts, only a few symptomatic treatment options currently exist [<xref rid="B10" ref-type="bibr">10</xref>].</p><p>However, adequate dementia management requires a wide range of interventions to help maximize the patient's independence, increase his/her self-confidence and relieve the burden to the caregiver [<xref rid="B11" ref-type="bibr">11</xref>]. We are in desperate need of readily available safe interventions that modify disease course [<xref rid="B12" ref-type="bibr">12</xref>]. In the last decades, also several natural products have been tested for preventing the onset of dementia or delaying its progression [<xref rid="B13" ref-type="bibr">13</xref>]. Despite being widely used and tested, the efficacy of such natural medication in the prevention and treatment of dementia still remains controversial.</p><p>MLC601 is a traditional Chinese medicine that has shown both neuroprotective and neurodegenerative properties in several controlled studies of ischemic injury to the brain [<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref>]. However, it has been shown that MLC601 is a possible modulator of amyloid precursor protein (APP) processing and has implications as a putative therapeutic strategy for the treatment of poststroke dementia and AD [<xref rid="B22" ref-type="bibr">22</xref>]. In a clinical trial study, MLC601 showed favorable tolerability and encouraging effectiveness on cognitive function in AD patients during 18 months of treatment when compared to rivastigmine [<xref rid="B23" ref-type="bibr">23</xref>].</p><p>In this study, we attempted to evaluate the effectiveness of MLC601 in the treatment of mild to moderate AD as compared to the 3 approved ChEIs donepezil, rivastigmine and galantamine. In addition, we aimed to determine the side effects in 4 study groups. For this reason, we monitored the cognitive changes and side effects during the 16-month follow-up.</p></sec><sec sec-type="materials|methods" id="sec1_2"><title>Materials and Methods</title><sec id="sec2_1"><title>Participants</title><p>Patients with mild to moderate AD who fulfilled our inclusion criteria were recruited for the study. The inclusion criteria were age &#x0003e;60 years, Mini-Mental State Examination (MMSE) scores ranging from 10 to 26, ability to sign an informed consent form and a possible diagnosis of AD. Diagnosis was made according to the criteria for AD of the American Psychiatric Association <italic>Diagnostic and Statistical Manual of Mental Disorders</italic>, ed 4 [<xref rid="B24" ref-type="bibr">24</xref>].</p><p>Brain magnetic resonance imaging was done to rule out significant central nervous system lesions. Ischemic dementia was excluded according to clinical and laboratory tests, brain imaging study, and a Hachinski Ischemic Scale [<xref rid="B25" ref-type="bibr">25</xref>] score &#x0003c;4. Exclusion criteria were: psychiatric or mental disorders, serious physical illness, other neurological diseases, hypothyroidism, diabetes mellitus, liver or renal disease, addiction, other causes of dementia than AD, being already on ChEI treatment at study entry, participation in another treatment trial within the prior 16 months and contraindications to ChEIs.</p></sec><sec id="sec2_2"><title>Study Design</title><p>We designed our study as a multicenter, nonblinded, randomized controlled clinical trial to evaluate the effectiveness and safety of MLC601 in the treatment of mild to moderate AD as compared to the 3 approved ChEIs donepezil, rivastigmine and galantamine. A total of 927 patients with AD were screened, and after considering the inclusion and exclusion criteria, 264 eligible volunteers with AD were randomly divided into 4 groups of 66; groups 1, 2, 3 and 4 received donepezil, rivastigmine, MLC601 and galantamine, respectively. A sample size of 54 in each group was calculated to detect a 5-point score difference in effect size with a standard deviation of 8 for 5% precision and 90% power. It was increased to 66 subjects to enhance power. Simple randomization was performed using computer-generated random allocation sequence. The study protocol is shown as a flowchart in figure <xref ref-type="fig" rid="F1">1</xref>.</p><p>MLC601 (NeuroAid, Moleac Pte. Ltd, Singapore; 0.4 g per capsule) was prescribed as one capsule three times daily. MLC601 contains 5 animal components (0.0665 g <italic>Hirudo</italic>, 0.0285 g <italic>Cornu saigae tataricae</italic>, 0.095 g <italic>Buthus martensii</italic>, 0.0665 g <italic>Eupolyphaga seu steleophaga</italic> and 0.0285 g <italic>Calculus bovisartifactus</italic>) and 9 herbal components (0.114 g radix <italic>Paeoniae rubra</italic>, 0.57 g radix astragali, 0.114 g radix <italic>Salvia miltiorrhizae</italic>, 0.114 g <italic>Rhizoma chuanxiong</italic>, 0.114 g radix <italic>Angelicae sinensis</italic>, 0.114 g radix polygalae, 0.114 g <italic>Prunus persica</italic>, 0.114 g <italic>Carthamus tinctorius</italic> and 0.114 g <italic>Rhizoma acori tatarinowii</italic>). Patients in the other 3 groups received standard medication of ChEIs according to clinical response and recommended maximum or tolerable dose.</p></sec><sec id="sec2_3"><title>Ethical Issues</title><p>The study protocol was explained to each patient and his/her caregivers, and they provided written informed consent. The study was designed in accordance with the Helsinki Declaration and approved by the Ethics Committee at Shahid Beheshti University of Medical Sciences. The participants were allowed to discontinue the study at any time. Medications other than the mentioned antidementia ones were allowed to be taken.</p></sec><sec id="sec2_4"><title>Outcome Measures</title><p>At screening, all patients underwent a detailed medical history taking, physical and neurological examinations, clinical interview, and laboratory evaluations. Almost all clinical trials on the symptomatic therapy for AD use MMSE and/or the Alzheimer's Disease Assessment Scale &#x02013; Cognitive subscale (ADAS-Cog) [<xref rid="B26" ref-type="bibr">26</xref>]. Therefore, all subjects underwent a clinical diagnostic interview and a cognitive/functional battery including MMSE and ADAS-Cog. Patients were visited every 4 months, and the score of cognition was recorded by the neurologists.</p></sec><sec id="sec2_5"><title>Alzheimer's Disease Assessment Scale &#x02013; Cognitive Subscale</title><p>ADAS-Cog was constructed by Rosen et al. [<xref rid="B27" ref-type="bibr">27</xref>] to measure the cognitive aspects of AD. The standard ADAS-Cog includes 11 items, of which 7 are short cognitive tests: Word recall, Naming (objects and fingers), (Following) Commands, Constructional praxis, Ideational praxis, Orientation and Word recognition, and 4 are scales rated by the clinician: Remembering test instructions, Spoken language ability, Word-finding difficulty and Comprehension [<xref rid="B28" ref-type="bibr">28</xref>]. The majority of studies with ADAS-Cog use the standard scale described above, which represents the most widely adopted cognitive outcome measure in AD trials. The score ranges from 0 to 70, with higher scores indicating greater cognitive impairment.</p></sec><sec id="sec2_6"><title>Mini-Mental State Examination</title><p>MMSE was used to measure the cognitive aspects of mental status [<xref rid="B29" ref-type="bibr">29</xref>]. It contains 10 items including Orientation, Registration, Attention, Recall, Language, Naming, Repetition, Comprehension, Reading ability, Writing ability and Visual construction. The MMSE scale ranges from 0 to 30, and the higher the score the better the cognitive performance.</p></sec><sec id="sec2_7"><title>Safety Measures</title><p>Safety was evaluated monthly by recording adverse events reported by the participants and their study partner and vital signs. We also performed physical and neurological examinations, and laboratory tests including complete cell blood count, serum blood urea nitrogen, aspartate aminotransferase, alanine transaminase, creatinine, calcium, phosphorus, sodium, potassium, prothrombin time, partial thromboplastin time, and international normalized ratio.</p></sec><sec id="sec2_8"><title>Statistical Analysis</title><p>The SPSS software, version 16.0 (SPSS Inc., Chicago, Ill., USA), was used to perform the statistical analyses. The level of significance was set at p &#x0003c; 0.05. The &#x003c7;<sup>2</sup> test and ANOVA were used to analyze qualitative and quantitative variables, respectively. In order to compare changes over time for MMSE and ADAS-Cog scores between the 4 patient groups, repeated measures analysis was performed.</p></sec></sec><sec sec-type="results" id="sec1_3"><title>Results</title><p>The baseline characteristics of the 264 patients are shown in table <xref ref-type="table" rid="T1">1</xref>. There were no significant differences in age, sex, marital status and baseline score of cognition among the 4 groups. Educational status did not differ statistically among groups (PV = 0.59; table <xref ref-type="table" rid="T2">2</xref>).</p><sec id="sec2_9"><title>Safety Profile</title><p>Thirty-nine patients (14.7%) left the study. Finally, 57 (86.4%; 63.1% female), 53 (80.3%; 54.7% female), 59 (89.4%; 54.2% female) and 56 (84.8%; 53.5% female) patients in group 1, 2, 3 and 4, respectively, completed 16 months of follow-up. The dropout numbers were not different among groups. The reasons for dropout were investigated and included death, patient's or caregiver's desire, unsatisfactory efficacy and presence of severe side effects (p = 0.52). The two most common causes of dropout were unsatisfactory efficacy (8.7%) and adverse effects (4.1%). The causes of dropout and dropout numbers are shown in table <xref ref-type="table" rid="T3">3</xref>. Two deaths due to pneumonia were registered in the donepezil and rivastigmine groups.</p><p>The mean number of side effects was statistically significant among groups (p &#x0003c; 0.0001) with the least events in the MLC601 group (table <xref ref-type="table" rid="T4">4</xref>). Frequency distribution of side effects is presented in table <xref ref-type="table" rid="T5">5</xref>.</p></sec><sec id="sec2_10"><title>Efficacy Profile</title><p>The mean MMSE scores and the mean changes from baseline at the different visits are shown in table <xref ref-type="table" rid="T6">6</xref>. The mean change in MMSE over 16 months for the donepezil group was &#x02212;0.50 points (&#x000b1;3.5), for the rivastigmine group it was &#x02212;0.56 points (&#x000b1;2.9), for the MLC601 group &#x02212;0.45 points (&#x000b1;1.9) and for the galantamine group &#x02212;0.43 points (&#x000b1;2.6).</p><p>The mean ADAS-Cog scores and the mean changes from baseline at the different visits are shown in table <xref ref-type="table" rid="T7">7</xref>. The mean change in ADAS-Cog during 16 months for the donepezil group was 1.6 points (&#x000b1;7.6), for the rivastigmine group it was 1.6 points (&#x000b1;6.7), for the MLC601 group 1.35 points (&#x000b1;5.3) and for the galantamine group 1.2 points (&#x000b1;6.1).</p><p>The mean differences of both MMSE and ADAS-Cog generally increased during the first 8 months. The trend of cognition changes based on the modifications over time of the MMSE (fig. <xref ref-type="fig" rid="F2">2</xref>) and ADAS-cog scores (fig. <xref ref-type="fig" rid="F3">3</xref>) did not differ significantly among groups (p = 0.92 for MMSE and p = 0.87 for ADAS-Cog).</p></sec></sec><sec sec-type="discussion" id="sec1_4"><title>Discussion</title><p>Current medications cannot cure AD but may help lessen or stabilize symptoms of AD for a limited time. There are five prescription drugs approved by the US Food and Drug Administration (FDA) &#x02013; donepezil, galantamine, rivastigmine, tacrine and memantine &#x02013; to treat its symptoms. The first 4 drugs are ChEIs, which can prevent the breakdown of acetylcholine involved in memory, judgment and other thought progress. However, these drugs have common side effects including nausea, vomiting, loss of appetite and increased frequency of bowel movements [<xref rid="B30" ref-type="bibr">30</xref>]. Additional evidence suggests that the response to ChEIs may be quite variable, with as many as 30-50% of patients showing no observable benefit [<xref rid="B31" ref-type="bibr">31</xref>,<xref rid="B32" ref-type="bibr">32</xref>], while a smaller proportion (up to 20%) may show a greater than average response (&#x02265;7-point ADAS-Cog improvement) [<xref rid="B33" ref-type="bibr">33</xref>,<xref rid="B34" ref-type="bibr">34</xref>]. In their systematic review, Raina et al. [<xref rid="B35" ref-type="bibr">35</xref>] concluded that treatment of dementia with ChEIs and memantine can result in a statistically significant but clinically marginal improvement in measures of cognition and global assessment of dementia.</p><p>Despite controversies, ChEIs have been promoted during the last 15 years as symptomatic treatment of mild to moderate AD. Several meta-analyses have reported a modest effect of ChEIs on cognition [<xref rid="B35" ref-type="bibr">35</xref>,<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B37" ref-type="bibr">37</xref>]. The exponential rise in the prevalence, incidence and cost of care for AD make finding therapeutic agents that can delay disease progression an urgent public health concern [<xref rid="B38" ref-type="bibr">38</xref>]. Therefore, promising new treatments to slow or stop the progress of AD are urgently needed [<xref rid="B39" ref-type="bibr">39</xref>]. The response to ChEIs varies within the AD population. Multiple factors have been outlined that enhance the response to ChEI treatment in AD [<xref rid="B40" ref-type="bibr">40</xref>]; however, there are no standard guidelines that define the response to treatment. The choice between ChEIs is largely based upon cost, individual patient tolerability and physician experience as their efficacy appears to be similar [<xref rid="B35" ref-type="bibr">35</xref>,<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B41" ref-type="bibr">41</xref>].</p><p>In a previous study, 124 patients with mild to moderate AD who had previously failed to tolerate or benefit from treatment with rivastigmine were switched to an MLC601 regimen. Two patients were lost to follow-up and 122 completed the 18-month trial. Improved cognitive function was observed in the first 6 months of the regimen (ADAS-Cog = &#x02212;3.1 &#x000b1; 10.1; MMSE = 1.2 &#x000b1; 3.0), and stabilization of cognitive decline was observed over the remaining 12 months (ADAS-Cog = &#x02212;1.6 &#x000b1; 7.6; MMSE = 0.8 &#x000b1; 4.2). Adverse effects were predominantly gastrointestinal and occurred in 7.3% of patients [<xref rid="B23" ref-type="bibr">23</xref>]. In the current study, the mean change in MMSE and ADAS-Cog over 16 months for the MLC601 group was &#x02212;0.45 and 1.35 points (&#x000b1;5.3), respectively. Cognition scores improved in the first 8 months and then declined slightly up to the 16th month in all 4 groups. Side effects were significantly lower in the MLC601 group compared to the other groups. In the 3 approved treatment groups, donepezil showed the lowest mean number of side effects (1.86), which was 3.6 times more than MLC601, and rivastigmine had the highest number of side effects, i.e. 5.6 times more than MLC601. Accordingly, MLC601 dramatically showed minimum adverse events among the 4 groups (1.86:0.51 = 3.6, and rivastigmine 2.81:0.51 = 5.6; table <xref ref-type="table" rid="T2">2</xref>). Tolerability is very important in patients with AD since the therapeutic effect is often compromised by the occurrence of adverse events and discontinuation of treatment [<xref rid="B42" ref-type="bibr">42</xref>].</p><p>Most studies on ChEIs were of short duration, i.e. 6 months, which limited their ability to detect a delay in the onset or progression of dementia [<xref rid="B35" ref-type="bibr">35</xref>]. Low completion rates are another difficulty of long-term studies of AD patients, both with or without treatment. Three-year completion rates range between 4 and 39% [<xref rid="B43" ref-type="bibr">43</xref>,<xref rid="B44" ref-type="bibr">44</xref>,<xref rid="B45" ref-type="bibr">45</xref>], making it difficult to fully comprehend the long-term outcomes of treatment in AD [<xref rid="B46" ref-type="bibr">46</xref>]. Because ethical constraints prohibit the use of long-term, placebo-controlled studies of ChEIs in AD, the analysis of results from open-label, long-term trials is important. In this study, we monitored the long-term efficacy of MLC601 during the extended follow-up duration over 16 months [<xref rid="B26" ref-type="bibr">26</xref>]. Such an adequate follow-up in our study is a notable evidence for monitoring the trend of changes in patients who are on 3 types of ChEIs. In addition, the withdrawal rate was low in this study, and only 14.7% of subjects left the study. This point is another advantage of the study.</p><p>There is convergent evidence that overproduction, aberrant aggregation, and decreased elimination of different forms of amyloid beta protein are critical events in the pathogenesis of AD and, therefore, treatment development has focused on these processes [<xref rid="B12" ref-type="bibr">12</xref>]. In AD, APP is preferentially processed via the amyloidogenic pathway, producing large amounts of amyloid beta protein that forms the major constituent of senile plaques and tau-containing neurofibrillary tangles [<xref rid="B22" ref-type="bibr">22</xref>]. Since MLC601 has some neuroprotective effects, it is possible that it may exert its neuroprotective effects via the regulation of APP processing. MLC601 is a possible modulator of APP processing. Lim et al. [<xref rid="B22" ref-type="bibr">22</xref>] found that MLC601 induced a decrease in APP and enhanced the secreted forms of APP&#x003b1; release, suggesting that MLC601 may act by promoting the processing of APP via the nonamyloidogenic pathway.</p><p>We did not specifically measure our patients' quality of life, activities of daily living, global outcome and behavior, which should be considered as study limitations. Neither the patients nor neurologists were blinded to medication.</p></sec><sec sec-type="conclusions" id="sec1_5"><title>Conclusion</title><p>MLC601 has shown a promising safety profile and also efficacy compared to the 3 FDA-approved ChEIs donepezil, rivastigmine and galantamine. There is a need to conduct more randomized controlled trials with a combination of MLC601 and ChEIs to find out whether MLC601 may provide additional cognitive and/or functional benefits in AD when combined with &#x02018;first-line&#x02019; treatments.</p></sec><sec id="sec1_6"><title>Disclosure Statement</title><p>The authors declare that they have no competing interests.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hippius</surname><given-names>H</given-names></name><name><surname>Neund&#x000f6;rfer</surname><given-names>G</given-names></name></person-group><article-title>The discovery of Alzheimer's disease</article-title><source>Dialogues Clin Neurosci</source><year>2003</year><volume>5</volume><fpage>101</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">22034141</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reitz</surname><given-names>C</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name></person-group><article-title>Epidemiology of Alzheimer disease</article-title><source>Nat Rev Neurol</source><year>2011</year><volume>7</volume><fpage>137</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">21304480</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferri</surname><given-names>CP</given-names></name><name><surname>Prince</surname><given-names>M</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Brodaty</surname><given-names>H</given-names></name><name><surname>Fratiglioni</surname><given-names>L</given-names></name><name><surname>Ganguli</surname><given-names>M</given-names></name><name><surname>Hall</surname><given-names>K</given-names></name><name><surname>Hasegawa</surname><given-names>K</given-names></name><name><surname>Hendrie</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Jorm</surname><given-names>A</given-names></name><name><surname>Mathers</surname><given-names>C</given-names></name><name><surname>Menezes</surname><given-names>PR</given-names></name><name><surname>Rimmer</surname><given-names>E</given-names></name><name><surname>Scazufca</surname><given-names>M</given-names></name></person-group><article-title>Alzheimer's Disease International: Global prevalence of dementia: a Delphi consensus study</article-title><source>Lancet</source><year>2005</year><volume>366</volume><fpage>2112</fpage><lpage>2117</lpage><pub-id pub-id-type="pmid">16360788</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Cole</surname><given-names>G</given-names></name></person-group><article-title>Alzheimer disease</article-title><source>JAMA</source><year>2002</year><volume>287</volume><fpage>2335</fpage><lpage>2338</lpage><pub-id pub-id-type="pmid">11988038</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>SL</given-names></name><name><surname>Friedhoff</surname><given-names>LT</given-names></name></person-group><article-title>The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial</article-title><source>The Donepezil Study Group. Dementia</source><year>1996</year><volume>7</volume><fpage>293</fpage><lpage>303</lpage></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000f6;sler</surname><given-names>M</given-names></name><name><surname>Anand</surname><given-names>R</given-names></name><name><surname>Cicin-Sain</surname><given-names>A</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Agid</surname><given-names>Y</given-names></name><name><surname>Dal-Bianco</surname><given-names>P</given-names></name><name><surname>St&#x000e4;helin</surname><given-names>HB</given-names></name><name><surname>Hartman</surname><given-names>R</given-names></name><name><surname>Gharabawi</surname><given-names>M</given-names></name></person-group><article-title>Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial</article-title><source>BMJ</source><year>1999</year><volume>318</volume><fpage>633</fpage><lpage>638</lpage><pub-id pub-id-type="pmid">10066203</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raskind</surname><given-names>MA</given-names></name><name><surname>Peskind</surname><given-names>ER</given-names></name><name><surname>Wessel</surname><given-names>T</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name></person-group><article-title>Galantamine in AD a 6-month randomized, placebo-controlled trial with a 6-month extension</article-title><source>The Galantamine USA-1 Study Group. Neurology</source><year>2000</year><volume>54</volume><fpage>2261</fpage><lpage>2268</lpage></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tariot</surname><given-names>PN</given-names></name><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Grossberg</surname><given-names>GT</given-names></name><name><surname>Graham</surname><given-names>SM</given-names></name><name><surname>McDonald</surname><given-names>S</given-names></name><name><surname>Gergel</surname><given-names>I</given-names></name></person-group><article-title>Memantine Study Group: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial</article-title><source>JAMA</source><year>2004</year><volume>291</volume><fpage>317</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">14734594</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doody</surname><given-names>RS</given-names></name></person-group><article-title>We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer's disease drug development</article-title><source>Alzheimers Dement</source><year>2008</year><volume>4</volume><issue>(suppl 1)</issue><fpage>S21</fpage><lpage>S25</lpage><pub-id pub-id-type="pmid">18631995</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heo</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>ST</given-names></name><name><surname>Oh</surname><given-names>MJ</given-names></name><name><surname>Park</surname><given-names>HJ</given-names></name><name><surname>Shim</surname><given-names>JY</given-names></name><name><surname>Chu</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name></person-group><article-title>Improvement of cognitive deficit in Alzheimer's disease patients by long term treatment with Korean red ginseng</article-title><source>J Ginseng Res</source><year>2011</year><volume>35</volume><fpage>457</fpage><lpage>461</lpage><pub-id pub-id-type="pmid">23717092</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>T&#x000e1;rraga</surname><given-names>L</given-names></name><name><surname>Boada</surname><given-names>M</given-names></name><name><surname>Modinos</surname><given-names>G</given-names></name><name><surname>Espinosa</surname><given-names>A</given-names></name><name><surname>Diego</surname><given-names>S</given-names></name><name><surname>Morera</surname><given-names>A</given-names></name><name><surname>Guitart</surname><given-names>M</given-names></name><name><surname>Balcells</surname><given-names>J</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>OL</given-names></name><name><surname>Becker</surname><given-names>JT</given-names></name></person-group><article-title>A randomised pilot study to assess the efficacy of an interactive, multimedia tool of cognitive stimulation in Alzheimer's disease</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2006</year><volume>77</volume><fpage>1116</fpage><lpage>1121</lpage><pub-id pub-id-type="pmid">16820420</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ringman</surname><given-names>JM</given-names></name><name><surname>Frautschy</surname><given-names>SA</given-names></name><name><surname>Teng</surname><given-names>E</given-names></name><name><surname>Begum</surname><given-names>AN</given-names></name><name><surname>Bardens</surname><given-names>J</given-names></name><name><surname>Beigi</surname><given-names>M</given-names></name><name><surname>Gylys</surname><given-names>KH</given-names></name><name><surname>Badmaev</surname><given-names>V</given-names></name><name><surname>Heath</surname><given-names>DD</given-names></name><name><surname>Apostolova</surname><given-names>LG</given-names></name><name><surname>Porter</surname><given-names>V</given-names></name><name><surname>Vanek</surname><given-names>Z</given-names></name><name><surname>Marshall</surname><given-names>GA</given-names></name><name><surname>Hellemann</surname><given-names>G</given-names></name><name><surname>Sugar</surname><given-names>C</given-names></name><name><surname>Masterman</surname><given-names>DL</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Cole</surname><given-names>GM</given-names></name></person-group><article-title>Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study</article-title><source>Alzheimers Res Ther</source><year>2012</year><volume>4</volume><fpage>43</fpage><pub-id pub-id-type="pmid">23107780</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canevelli</surname><given-names>M</given-names></name><name><surname>Adali</surname><given-names>N</given-names></name><name><surname>Kelaiditi</surname><given-names>E</given-names></name><name><surname>Cantet</surname><given-names>C</given-names></name><name><surname>Ousset</surname><given-names>PJ</given-names></name><name><surname>Cesari</surname><given-names>M</given-names></name></person-group><article-title>ICTUS/DSA Group: Effects of <italic>Gingko biloba</italic> supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: data from the ICTUS study</article-title><source>Phytomedicine</source><year>2014</year><volume>21</volume><fpage>888</fpage><lpage>892</lpage><pub-id pub-id-type="pmid">24548724</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintard</surname><given-names>H</given-names></name><name><surname>Lorivel</surname><given-names>T</given-names></name><name><surname>Gandin</surname><given-names>C</given-names></name><name><surname>Lazdunski</surname><given-names>M</given-names></name><name><surname>Heurteaux</surname><given-names>C</given-names></name></person-group><article-title>MLC901, a traditional Chinese medicine induces neuroprotective and neuroregenerative benefits after traumatic brain injury in rats</article-title><source>Neuroscience</source><year>2014</year><volume>277</volume><fpage>72</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">24993477</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CL</given-names></name><name><surname>Young</surname><given-names>SH</given-names></name><name><surname>Gan</surname><given-names>HH</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Lao</surname><given-names>AY</given-names></name><name><surname>Baroque</surname><given-names>AC</given-names><suffix>2nd</suffix></name><name><surname>Chang</surname><given-names>HM</given-names></name><name><surname>Hiyadan</surname><given-names>JH</given-names></name><name><surname>Chua</surname><given-names>CL</given-names></name><name><surname>Advincula</surname><given-names>JM</given-names></name><name><surname>Muengtaweepongsa</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>BP</given-names></name><name><surname>de Silva</surname><given-names>HA</given-names></name><name><surname>Towanabut</surname><given-names>S</given-names></name><name><surname>Suwanwela</surname><given-names>NC</given-names></name><name><surname>Poungvarin</surname><given-names>N</given-names></name><name><surname>Chankrachang</surname><given-names>S</given-names></name><name><surname>Wong</surname><given-names>KS</given-names></name><name><surname>Eow</surname><given-names>GB</given-names></name><name><surname>Navarro</surname><given-names>JC</given-names></name><name><surname>Venketasubramanian</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>CF</given-names></name><name><surname>Bousser</surname><given-names>MG</given-names></name></person-group><article-title>CHIMES Study Investigators: Chinese medicine neuroaid efficacy on stroke recovery: a double-blind, placebo-controlled, randomized study</article-title><source>Stroke</source><year>2013</year><volume>44</volume><fpage>2093</fpage><lpage>2100</lpage><pub-id pub-id-type="pmid">23780952</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiqui</surname><given-names>FJ</given-names></name><name><surname>Venketasubramanian</surname><given-names>N</given-names></name><name><surname>Chan</surname><given-names>ES</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name></person-group><article-title>Efficacy and safety of MLC601 (NeuroAiD&#x000ae;), a traditional Chinese medicine, in poststroke recovery: a systematic review</article-title><source>Cerebrovasc Dis</source><year>2013</year><volume>35</volume><issue>(suppl 1)</issue><fpage>8</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">23548914</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname><given-names>JC</given-names></name><name><surname>Molina</surname><given-names>MC</given-names></name><name><surname>Baroque Ii</surname><given-names>AC</given-names></name><name><surname>Lokin</surname><given-names>JK</given-names></name></person-group><article-title>The use of NeuroAiD (MLC601) in postischemic stroke patients</article-title><source>Rehabil Res Pract</source><year>2012</year><volume>2012</volume><fpage>506387</fpage><pub-id pub-id-type="pmid">23304514</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintard</surname><given-names>H</given-names></name><name><surname>Borsotto</surname><given-names>M</given-names></name><name><surname>Veyssiere</surname><given-names>J</given-names></name><name><surname>Gandin</surname><given-names>C</given-names></name><name><surname>Labbal</surname><given-names>F</given-names></name><name><surname>Widmann</surname><given-names>C</given-names></name><name><surname>Lazdunski</surname><given-names>M</given-names></name><name><surname>Heurteaux</surname><given-names>C</given-names></name></person-group><article-title>MLC901, a traditional Chinese medicine protects the brain against global ischemia</article-title><source>Neuropharmacology</source><year>2011</year><volume>61</volume><fpage>622</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">21605573</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heurteaux</surname><given-names>C</given-names></name><name><surname>Gandin</surname><given-names>C</given-names></name><name><surname>Borsotto</surname><given-names>M</given-names></name><name><surname>Widmann</surname><given-names>C</given-names></name><name><surname>Brau</surname><given-names>F</given-names></name><name><surname>Lhuillier</surname><given-names>M</given-names></name><name><surname>Onteniente</surname><given-names>B</given-names></name><name><surname>Lazdunski</surname><given-names>M</given-names></name></person-group><article-title>Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo</article-title><source>Neuropharmacology</source><year>2010</year><volume>58</volume><fpage>987</fpage><lpage>1001</lpage><pub-id pub-id-type="pmid">20064536</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venketasubramanian</surname><given-names>N</given-names></name><name><surname>Young</surname><given-names>S</given-names></name><name><surname>Tay</surname><given-names>SS</given-names></name><name><surname>Chang</surname><given-names>HM</given-names></name><name><surname>Umapathi</surname><given-names>T</given-names></name><name><surname>Chan</surname><given-names>B</given-names></name><name><surname>de Silva</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>L</given-names></name><name><surname>Navarro</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>YD</given-names></name><name><surname>Tan</surname><given-names>SB</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name></person-group><article-title>Chinese medicine NeuroAiD efficacy stroke recovery-extension study (CHIMES-E study): an observational multicentre study to investigate the longer-term efficacy of NeuroAiD in stroke recovery</article-title><source>Cerebrovasc Dis</source><year>2013</year><volume>35</volume><issue>(suppl 1)</issue><fpage>18</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">23548915</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>SH</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Koh</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Chan</surname><given-names>BP</given-names></name><name><surname>Chang</surname><given-names>HM</given-names></name><name><surname>Venketasubramanian</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name></person-group><article-title>CHIMES Investigators: Safety profile of MLC601 (NeuroAiD) in acute ischemic stroke patients: a Singaporean substudy of the Chinese medicine neuroAiD efficacy on stroke recovery study</article-title><source>Cerebrovasc Dis</source><year>2010</year><volume>30</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">20395679</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>YA</given-names></name><name><surname>Murray</surname><given-names>LA</given-names></name><name><surname>Lai</surname><given-names>MK</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name></person-group><article-title>NeuroAiD&#x000ae; (MLC601) and amyloid precursor protein processing</article-title><source>Cerebrovasc Dis</source><year>2013</year><volume>35</volume><issue>(suppl 1)</issue><fpage>30</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">23548917</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harandi</surname><given-names>AA</given-names></name><name><surname>Ashrafi</surname><given-names>F</given-names></name><name><surname>Tabatabaei</surname><given-names>M</given-names></name><name><surname>Ghorbani</surname><given-names>A</given-names></name><name><surname>Hatamian</surname><given-names>HR</given-names></name><name><surname>Pakdaman</surname><given-names>H</given-names></name><name><surname>Ilkhani</surname><given-names>M</given-names></name><name><surname>Gharagozli</surname><given-names>K</given-names></name><name><surname>et</surname><given-names>al</given-names></name></person-group><article-title>Efficacy and tolerability of MlC601 in patients with mild to moderate Alzheimer disease who were unable to tolerate or failed to benefit from treatment with rivastigmine</article-title><source>Br J Med Med Res</source><year>2013</year><volume>3</volume><fpage>341</fpage><lpage>350</lpage></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="book"><collab>American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV)</collab><year>1994</year><publisher-loc>Washington</publisher-loc><publisher-name>American Psychiatric Press</publisher-name><fpage>147</fpage><lpage>154</lpage></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hachinski</surname><given-names>VC</given-names></name><name><surname>Lassen</surname><given-names>NA</given-names></name><name><surname>Marshall</surname><given-names>J</given-names></name></person-group><article-title>Multi-infarct dementia: a cause of mental deterioration in the elderly</article-title><source>Lancet</source><year>1974</year><volume>2</volume><fpage>207</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">4135618</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Persson</surname><given-names>CM</given-names></name><name><surname>Wallin</surname><given-names>AK</given-names></name><name><surname>Levander</surname><given-names>S</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name></person-group><article-title>Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil</article-title><source>BMC Neurol</source><year>2009</year><volume>9</volume><fpage>7</fpage><pub-id pub-id-type="pmid">19208247</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>WG</given-names></name><name><surname>Mohs</surname><given-names>RC</given-names></name><name><surname>Davis</surname><given-names>KL</given-names></name></person-group><article-title>A new rating scale for Alzheimer's disease</article-title><source>Am J Psychiatry</source><year>1984</year><volume>141</volume><fpage>1356</fpage><lpage>1364</lpage><pub-id pub-id-type="pmid">6496779</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weyer</surname><given-names>G</given-names></name><name><surname>Erzigkeit</surname><given-names>H</given-names></name><name><surname>Kanowski</surname><given-names>S</given-names></name><name><surname>Ihl</surname><given-names>R</given-names></name><name><surname>Hadler</surname><given-names>D</given-names></name></person-group><article-title>Alzheimer's Disease Assessment Scale: reliability and validity in a multicenter clinical trial</article-title><source>Int Psychogeriatr</source><year>1997</year><volume>9</volume><fpage>123</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">9309486</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folstein</surname><given-names>MF</given-names></name><name><surname>Folstein</surname><given-names>SE</given-names></name><name><surname>McHugh</surname><given-names>PR</given-names></name></person-group><article-title>&#x02018;Mini-mental state&#x02019;</article-title><source>A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res</source><year>1975</year><volume>12</volume><fpage>189</fpage><lpage>198</lpage></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="other"><collab>Alzheimer's Association: FDA-Approved Treatment for Alzheimer's</collab><source><ext-link ext-link-type="uri" xlink:href="http://www.alz.org">http://www.alz.org</ext-link> (accessed January 29, 2013)</source></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>JL</given-names></name></person-group><article-title>Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations</article-title><source>Am J Geriatr Psychiatry</source><year>2003</year><volume>11</volume><fpage>131</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">12611743</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>CM</given-names></name><name><surname>Karlawish</surname><given-names>JH</given-names></name></person-group><article-title>Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies</article-title><source>Ann Intern Med</source><year>2003</year><volume>138</volume><fpage>400</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">12614093</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langa</surname><given-names>KM</given-names></name><name><surname>Foster</surname><given-names>NL</given-names></name><name><surname>Larson</surname><given-names>EB</given-names></name></person-group><article-title>Mixed dementia: emerging concepts and therapeutic implications</article-title><source>JAMA</source><year>2004</year><volume>292</volume><fpage>2901</fpage><lpage>2908</lpage><pub-id pub-id-type="pmid">15598922</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grossberg</surname><given-names>GT</given-names></name><name><surname>Desai</surname><given-names>AK</given-names></name></person-group><article-title>Management of Alzheimer's disease</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2003</year><volume>58</volume><fpage>331</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">12663697</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raina</surname><given-names>P</given-names></name><name><surname>Santaguida</surname><given-names>P</given-names></name><name><surname>Ismaila</surname><given-names>A</given-names></name><name><surname>Patterson</surname><given-names>C</given-names></name><name><surname>Cowan</surname><given-names>D</given-names></name><name><surname>Levine</surname><given-names>M</given-names></name><name><surname>Booker</surname><given-names>L</given-names></name><name><surname>Oremus</surname><given-names>M</given-names></name></person-group><article-title>Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline</article-title><source>Ann Intern Med</source><year>2008</year><volume>148</volume><fpage>379</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">18316756</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birks</surname><given-names>JS</given-names></name><name><surname>Melzer</surname><given-names>D</given-names></name><name><surname>Beppu</surname><given-names>H</given-names></name></person-group><article-title>Donepezil for mild and moderate Alzheimer's disease</article-title><source>Cochrane Database Syst Rev 2000;CD001190</source></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trinh</surname><given-names>NH</given-names></name><name><surname>Hoblyn</surname><given-names>J</given-names></name><name><surname>Mohanty</surname><given-names>S</given-names></name><name><surname>Yaffe</surname><given-names>K</given-names></name></person-group><article-title>Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis</article-title><source>JAMA</source><year>2003</year><volume>289</volume><fpage>210</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">12517232</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shinto</surname><given-names>L</given-names></name><name><surname>Quinn</surname><given-names>J</given-names></name><name><surname>Montine</surname><given-names>T</given-names></name><name><surname>Dodge</surname><given-names>HH</given-names></name><name><surname>Woodward</surname><given-names>W</given-names></name><name><surname>Baldauf-Wagner</surname><given-names>S</given-names></name><name><surname>Waichunas</surname><given-names>D</given-names></name><name><surname>Bumgarner</surname><given-names>L</given-names></name><name><surname>Bourdette</surname><given-names>D</given-names></name><name><surname>Silbert</surname><given-names>L</given-names></name><name><surname>Kaye</surname><given-names>J</given-names></name></person-group><article-title>A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease</article-title><source>J Alzheimers Dis</source><year>2014</year><volume>38</volume><fpage>111</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">24077434</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>JP</given-names></name></person-group><article-title>Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e74916</fpage><pub-id pub-id-type="pmid">24086396</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanct&#x000f4;t</surname><given-names>KL</given-names></name><name><surname>Herrmann</surname><given-names>N</given-names></name><name><surname>LouLou</surname><given-names>MM</given-names></name></person-group><article-title>Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease</article-title><source>J Psychiatry Neurosci</source><year>2003</year><volume>28</volume><fpage>13</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">12587847</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qaseem</surname><given-names>A</given-names></name><name><surname>Snow</surname><given-names>V</given-names></name><name><surname>Cross</surname><given-names>JT</given-names><suffix>Jr</suffix></name><name><surname>Forciea</surname><given-names>MA</given-names></name><name><surname>Hopkins</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Shekelle</surname><given-names>P</given-names></name><name><surname>Adelman</surname><given-names>A</given-names></name><name><surname>Mehr</surname><given-names>D</given-names></name><name><surname>Schellhase</surname><given-names>K</given-names></name><name><surname>Campos-Outcalt</surname><given-names>D</given-names></name><name><surname>Santaguida</surname><given-names>P</given-names></name><name><surname>Owens</surname><given-names>DK</given-names></name></person-group><article-title>American College of Physicians/American Academy of Family Physicians Panel on Dementia: Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians</article-title><source>Ann Intern Med</source><year>2008</year><volume>148</volume><fpage>370</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">18316755</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanct&#x000f4;t</surname><given-names>KL</given-names></name><name><surname>Herrmann</surname><given-names>N</given-names></name><name><surname>Yau</surname><given-names>KK</given-names></name><name><surname>Khan</surname><given-names>LR</given-names></name><name><surname>Liu</surname><given-names>BA</given-names></name><name><surname>LouLou</surname><given-names>MM</given-names></name><name><surname>et</surname><given-names>al</given-names></name></person-group><article-title>Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis</article-title><source>CMAJ</source><year>2003</year><volume>169</volume><fpage>557</fpage><lpage>564</lpage><pub-id pub-id-type="pmid">12975222</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyle</surname><given-names>S</given-names></name><name><surname>Grizzell</surname><given-names>M</given-names></name><name><surname>Willmott</surname><given-names>S</given-names></name><name><surname>Benbow</surname><given-names>S</given-names></name><name><surname>Clark</surname><given-names>M</given-names></name><name><surname>Jolley</surname><given-names>D</given-names></name></person-group><article-title>Treatment of a whole population sample of Alzheimer's disease with donepezil over a 4-year period: lessons learned</article-title><source>Dement Geriatr Cogn Disord</source><year>2008</year><volume>25</volume><fpage>226</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">18230972</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallin</surname><given-names>AK</given-names></name><name><surname>Gustafson</surname><given-names>L</given-names></name><name><surname>Sj&#x000f6;gren</surname><given-names>M</given-names></name><name><surname>Wattmo</surname><given-names>C</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name></person-group><article-title>Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy</article-title><source>Dement Geriatr Cogn Disord</source><year>2004</year><volume>18</volume><fpage>197</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">15211076</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winblad</surname><given-names>B</given-names></name><name><surname>Wimo</surname><given-names>A</given-names></name><name><surname>Engedal</surname><given-names>K</given-names></name><name><surname>Soininen</surname><given-names>H</given-names></name><name><surname>Verhey</surname><given-names>F</given-names></name><name><surname>Waldemar</surname><given-names>G</given-names></name><name><surname>Wetterholm</surname><given-names>AL</given-names></name><name><surname>Haglund</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Schindler</surname><given-names>R</given-names></name></person-group><article-title>3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy</article-title><source>Dement Geriatr Cogn Disord</source><year>2006</year><volume>21</volume><fpage>353</fpage><lpage>363</lpage><pub-id pub-id-type="pmid">16508298</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallin</surname><given-names>AK</given-names></name><name><surname>Wattmo</surname><given-names>C</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name></person-group><article-title>Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting</article-title><source>Neuropsychiatr Dis Treat</source><year>2011</year><volume>7</volume><fpage>565</fpage><lpage>576</lpage><pub-id pub-id-type="pmid">22003296</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>The profile of the study.</p></caption><graphic xlink:href="dee-0005-0096-g01"/></fig><fig id="F2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Mean changes in MMSE score from baseline in the 4 groups of patients with AD.</p></caption><graphic xlink:href="dee-0005-0096-g02"/></fig><fig id="F3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Mean changes in ADAS-Cog score from baseline in the 4 groups of patients with AD.</p></caption><graphic xlink:href="dee-0005-0096-g03"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of the subjects</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Donepezil</th><th align="left" rowspan="1" colspan="1">Rivastigmine</th><th align="left" rowspan="1" colspan="1">MLC601</th><th align="left" rowspan="1" colspan="1">Galantamine</th><th align="left" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">_</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="left" rowspan="1" colspan="1">71.8&#x000b1; 5.5</td><td align="left" rowspan="1" colspan="1">73.2 &#x000b1; 4.7</td><td align="left" rowspan="1" colspan="1">71.8 &#x000b1; 5.7</td><td align="left" rowspan="1" colspan="1">72.5 &#x000b1; 5.2</td><td align="left" rowspan="1" colspan="1">0.375</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">41 (62.1%)</td><td align="left" rowspan="1" colspan="1">35 (53.0%)</td><td align="left" rowspan="1" colspan="1">37 (56.1%)</td><td align="left" rowspan="1" colspan="1">37 (56.1%)</td><td align="left" rowspan="1" colspan="1">0.759</td></tr><tr><td align="left" rowspan="1" colspan="1">Married</td><td align="left" rowspan="1" colspan="1">55 (83.3%)</td><td align="left" rowspan="1" colspan="1">56 (84.8%)</td><td align="left" rowspan="1" colspan="1">58 (87.9%)</td><td align="left" rowspan="1" colspan="1">57 (86.4%)</td><td align="left" rowspan="1" colspan="1">0.893</td></tr><tr><td align="left" rowspan="1" colspan="1">MMSE</td><td align="left" rowspan="1" colspan="1">17.6&#x000b1; 2.8</td><td align="left" rowspan="1" colspan="1">17.1 &#x000b1; 3.1</td><td align="left" rowspan="1" colspan="1">17.7 &#x000b1; 1.6</td><td align="left" rowspan="1" colspan="1">17.9 &#x000b1; 1.9</td><td align="left" rowspan="1" colspan="1">0.303</td></tr><tr><td align="left" rowspan="1" colspan="1">ADAS-Cog</td><td align="left" rowspan="1" colspan="1">27.8 &#x000b1; 6.5</td><td align="left" rowspan="1" colspan="1">29.6 &#x000b1; 7.7</td><td align="left" rowspan="1" colspan="1">27.5 &#x000b1; 4.1</td><td align="left" rowspan="1" colspan="1">27.3 &#x000b1; 5.0</td><td align="left" rowspan="1" colspan="1">0.100</td></tr></tbody></table></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Educational status in the 4 study groups</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th align="left" rowspan="1" colspan="1">Education</th><th align="left" rowspan="1" colspan="1">Donepezil</th><th align="left" rowspan="1" colspan="1">Rivastigmine</th><th align="left" rowspan="1" colspan="1">MLC601</th><th align="left" rowspan="1" colspan="1">Galantamine</th><th align="left" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Illiterate</td><td align="left" rowspan="1" colspan="1">6 (9.1%)</td><td align="left" rowspan="1" colspan="1">4 (6.1%)</td><td align="left" rowspan="1" colspan="1">2 (3.0%)</td><td align="left" rowspan="1" colspan="1">1 (1.5%)</td><td align="left" rowspan="1" colspan="1">13 (4.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Lettered</td><td align="left" rowspan="1" colspan="1">8 (12.1%)</td><td align="left" rowspan="1" colspan="1">5 (7.6%)</td><td align="left" rowspan="1" colspan="1">6 (9.1%)</td><td align="left" rowspan="1" colspan="1">8 (12.1%)</td><td align="left" rowspan="1" colspan="1">27 (10.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Middle school</td><td align="left" rowspan="1" colspan="1">7 (10.6%)</td><td align="left" rowspan="1" colspan="1">11 (16.7%)</td><td align="left" rowspan="1" colspan="1">13 (19.7%)</td><td align="left" rowspan="1" colspan="1">9 (13.6%)</td><td align="left" rowspan="1" colspan="1">40 (15.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diploma</td><td align="left" rowspan="1" colspan="1">32 (48.5%)</td><td align="left" rowspan="1" colspan="1">26 (39.4%)</td><td align="left" rowspan="1" colspan="1">31 (47.0%)</td><td align="left" rowspan="1" colspan="1">30 (45.5%)</td><td align="left" rowspan="1" colspan="1">119 (45.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">College</td><td align="left" rowspan="1" colspan="1">13 (19.7%)</td><td align="left" rowspan="1" colspan="1">20 (30.3%)</td><td align="left" rowspan="1" colspan="1">14 (21.2%)</td><td align="left" rowspan="1" colspan="1">18 (27.3%)</td><td align="left" rowspan="1" colspan="1">65 (24.6%)</td></tr></tbody></table></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Causes of dropout and dropout number</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th align="left" rowspan="1" colspan="1">Causes of dropout</th><th align="left" rowspan="1" colspan="1">Donepezil</th><th align="left" rowspan="1" colspan="1">Rivastigmine</th><th align="left" rowspan="1" colspan="1">MLC601</th><th align="left" rowspan="1" colspan="1">Galantamine</th><th align="left" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">No exit</td><td align="left" rowspan="1" colspan="1">57 (86.4%)</td><td align="left" rowspan="1" colspan="1">53 (80.3%)</td><td align="left" rowspan="1" colspan="1">59 (89.4%)</td><td align="left" rowspan="1" colspan="1">56 (84.8%)</td><td align="left" rowspan="1" colspan="1">225 (85.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Patient's or caregiver's desire</td><td align="left" rowspan="1" colspan="1">1 (1.5%)</td><td align="left" rowspan="1" colspan="1">1 (1.5%)</td><td align="left" rowspan="1" colspan="1">1 (1.5%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3 (1.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Adverse effects</td><td align="left" rowspan="1" colspan="1">2 (3.0%)</td><td align="left" rowspan="1" colspan="1">5 (7.6%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4 (6.1%)</td><td align="left" rowspan="1" colspan="1">11 (4.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Unsatisfactory efficacy</td><td align="left" rowspan="1" colspan="1">5 (7.6%)</td><td align="left" rowspan="1" colspan="1">6 (9.1%)</td><td align="left" rowspan="1" colspan="1">6 (9.1%)</td><td align="left" rowspan="1" colspan="1">6 (9.1%)</td><td align="left" rowspan="1" colspan="1">23 (8.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Death</td><td align="left" rowspan="1" colspan="1">1 (1.5%)</td><td align="left" rowspan="1" colspan="1">1 (1.5%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2 (0.7%)</td></tr></tbody></table></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Mean of side effects in the 4 study groups</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Number</th><th align="left" rowspan="1" colspan="1">Mean &#x000b1; SD</th><th align="left" colspan="2" rowspan="1">95% confidence interval<hr/></th><th align="left" rowspan="1" colspan="1">Minimum</th><th align="left" rowspan="1" colspan="1">Maximum</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">lower bound</th><th align="left" rowspan="1" colspan="1">upper bound</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Donepezil</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">1.86 &#x000b1; 2.49</td><td align="left" rowspan="1" colspan="1">1.24</td><td align="left" rowspan="1" colspan="1">2.48</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">Rivastigmine</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">2.86 &#x000b1; 3.28</td><td align="left" rowspan="1" colspan="1">2.05</td><td align="left" rowspan="1" colspan="1">3.67</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">MLC601</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">0.51 &#x000b1; 1.29</td><td align="left" rowspan="1" colspan="1">0.19</td><td align="left" rowspan="1" colspan="1">0.83</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">Galantamine</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">2.37 &#x000b1; 3.0</td><td align="left" rowspan="1" colspan="1">1.64</td><td align="left" rowspan="1" colspan="1">3.11</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">263</td><td align="left" rowspan="1" colspan="1">1.90 &#x000b1; 2.76</td><td align="left" rowspan="1" colspan="1">0.17</td><td align="left" rowspan="1" colspan="1">1.56</td><td align="left" rowspan="1" colspan="1">2.24</td><td align="left" rowspan="1" colspan="1">10</td></tr></tbody></table></table-wrap><table-wrap id="T5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Frequency distribution of side effects in the 4 study groups</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th align="left" rowspan="1" colspan="1">Side effect</th><th align="left" rowspan="1" colspan="1">Donepezil</th><th align="left" rowspan="1" colspan="1">Rivastigmine</th><th align="left" rowspan="1" colspan="1">MLC601</th><th align="left" rowspan="1" colspan="1">Galantamine</th><th align="left" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Nausea</td><td align="left" rowspan="1" colspan="1">14 (21.2%)</td><td align="left" rowspan="1" colspan="1">15 (22.7%)</td><td align="left" rowspan="1" colspan="1">6 (9.1%)</td><td align="left" rowspan="1" colspan="1">21 (31.8%)</td><td align="left" rowspan="1" colspan="1">0.01<xref ref-type="table-fn" rid="T5F1"><sup>*</sup></xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Vomiting</td><td align="left" rowspan="1" colspan="1">4 (6.1%)</td><td align="left" rowspan="1" colspan="1">8 (12.1%)</td><td align="left" rowspan="1" colspan="1">1 (1.5%)</td><td align="left" rowspan="1" colspan="1">10 (15.2%)</td><td align="left" rowspan="1" colspan="1">0.02<xref ref-type="table-fn" rid="T5F1"><sup>*</sup></xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Diarrhea</td><td align="left" rowspan="1" colspan="1">5 (7.6%)</td><td align="left" rowspan="1" colspan="1">9 (13.6%)</td><td align="left" rowspan="1" colspan="1">3 (4.5%)</td><td align="left" rowspan="1" colspan="1">5 (7.6%)</td><td align="left" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">Anorexia</td><td align="left" rowspan="1" colspan="1">15 (23.1%)</td><td align="left" rowspan="1" colspan="1">11 (16.7%)</td><td align="left" rowspan="1" colspan="1">4 (6.1%)</td><td align="left" rowspan="1" colspan="1">17 (25.8%)</td><td align="left" rowspan="1" colspan="1">0.01<xref ref-type="table-fn" rid="T5F1"><sup>*</sup></xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Weight loss</td><td align="left" rowspan="1" colspan="1">4 (6.1%)</td><td align="left" rowspan="1" colspan="1">7 (10.6%)</td><td align="left" rowspan="1" colspan="1">1 (1.5%)</td><td align="left" rowspan="1" colspan="1">3 (4.5%)</td><td align="left" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" rowspan="1" colspan="1">Abdominal discomfort</td><td align="left" rowspan="1" colspan="1">3 (4.5%)</td><td align="left" rowspan="1" colspan="1">7 (10.6%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">9 (13.6%)</td><td align="left" rowspan="1" colspan="1">0.01<xref ref-type="table-fn" rid="T5F1"><sup>*</sup></xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Tenesmus</td><td align="left" rowspan="1" colspan="1">4 (6.1%)</td><td align="left" rowspan="1" colspan="1">14 (21.2%)</td><td align="left" rowspan="1" colspan="1">4 (6.1%)</td><td align="left" rowspan="1" colspan="1">4 (6.1%)</td><td align="left" rowspan="1" colspan="1">0.005<xref ref-type="table-fn" rid="T5F1"><sup>*</sup></xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Abdominal pain</td><td align="left" rowspan="1" colspan="1">8 (12.1%)</td><td align="left" rowspan="1" colspan="1">9 (13.6%)</td><td align="left" rowspan="1" colspan="1">4 (6.1%)</td><td align="left" rowspan="1" colspan="1">10 (15.2%)</td><td align="left" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" rowspan="1" colspan="1">No cardiac chest pain</td><td align="left" rowspan="1" colspan="1">8 (12.1%)</td><td align="left" rowspan="1" colspan="1">7 (10.6%)</td><td align="left" rowspan="1" colspan="1">3 (4.5%)</td><td align="left" rowspan="1" colspan="1">13 (19.7%)</td><td align="left" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">Fatigue</td><td align="left" rowspan="1" colspan="1">2 (3.0%)</td><td align="left" rowspan="1" colspan="1">9 (13.6%)</td><td align="left" rowspan="1" colspan="1">3 (4.5%)</td><td align="left" rowspan="1" colspan="1">5 (7.6%)</td><td align="left" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1">Sialorrhea</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1 (1.5%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4 (6.1%)</td><td align="left" rowspan="1" colspan="1">0.03<xref ref-type="table-fn" rid="T5F1"><sup>*</sup></xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Constipation</td><td align="left" rowspan="1" colspan="1">9 (13.6%)</td><td align="left" rowspan="1" colspan="1">10 (15.2%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">6 (9.1%)</td><td align="left" rowspan="1" colspan="1">0.01<xref ref-type="table-fn" rid="T5F1"><sup>*</sup></xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Hyperhidrosis</td><td align="left" rowspan="1" colspan="1">3 (4.5%)</td><td align="left" rowspan="1" colspan="1">3 (4.5%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2 (3.0%)</td><td align="left" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastrointestinal bleeding</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1 (1.5%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2 (3.0%)</td><td align="left" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiac arrhythmia</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1 (1.5%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.39</td></tr><tr><td align="left" rowspan="1" colspan="1">Palpitation</td><td align="left" rowspan="1" colspan="1">5 (7.6%)</td><td align="left" rowspan="1" colspan="1">4 (6.1%)</td><td align="left" rowspan="1" colspan="1">1 (1.5%)</td><td align="left" rowspan="1" colspan="1">5 (7.6%)</td><td align="left" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" rowspan="1" colspan="1">Light-headedness</td><td align="left" rowspan="1" colspan="1">2 (3.0%)</td><td align="left" rowspan="1" colspan="1">8 (12.1%)</td><td align="left" rowspan="1" colspan="1">2 (3.0%)</td><td align="left" rowspan="1" colspan="1">4 (6.1%)</td><td align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">Hallucination</td><td align="left" rowspan="1" colspan="1">3 (4.5%)</td><td align="left" rowspan="1" colspan="1">3 (4.5%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1 (1.5%)</td><td align="left" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" rowspan="1" colspan="1">Drowsiness</td><td align="left" rowspan="1" colspan="1">1 (1.5%)</td><td align="left" rowspan="1" colspan="1">5 (7.6%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.009<xref ref-type="table-fn" rid="T5F1"><sup>*</sup></xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Depression</td><td align="left" rowspan="1" colspan="1">2 (3.0%)</td><td align="left" rowspan="1" colspan="1">5 (7.6%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2 (3.0%)</td><td align="left" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">Dizziness</td><td align="left" rowspan="1" colspan="1">4 (6.1%)</td><td align="left" rowspan="1" colspan="1">15 (22.7%)</td><td align="left" rowspan="1" colspan="1">1 (1.5%)</td><td align="left" rowspan="1" colspan="1">8 (12.1%)</td><td align="left" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="T5F1"><sup>*</sup></xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Headache</td><td align="left" rowspan="1" colspan="1">9 (13.6%)</td><td align="left" rowspan="1" colspan="1">14 (21.2%)</td><td align="left" rowspan="1" colspan="1">1 (1.5%)</td><td align="left" rowspan="1" colspan="1">13 (19.7%)</td><td align="left" rowspan="1" colspan="1">0.004<xref ref-type="table-fn" rid="T5F1"><sup>*</sup></xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Insomnia</td><td align="left" rowspan="1" colspan="1">11 (16.7%)</td><td align="left" rowspan="1" colspan="1">16 (24.2%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">8 (12.1%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="table-fn" rid="T5F1"><sup>*</sup></xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Confusion</td><td align="left" rowspan="1" colspan="1">5 (7.6%)</td><td align="left" rowspan="1" colspan="1">7 (10.6%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">5 (7.6%)</td><td align="left" rowspan="1" colspan="1">0.08</td></tr></tbody></table><table-wrap-foot><fn id="T5F1"><label>*</label><p>p &#x0003c; 0.05, statistically significant.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Means and standard deviations of MMSE scores in each group</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th align="left" rowspan="1" colspan="1">Group</th><th align="left" rowspan="1" colspan="1">Baseline</th><th align="left" rowspan="1" colspan="1">4th month</th><th align="left" rowspan="1" colspan="1">8th month</th><th align="left" rowspan="1" colspan="1">12th month</th><th align="left" rowspan="1" colspan="1">16th month</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Donepezil</td><td align="left" rowspan="1" colspan="1">17.66 (2.86)</td><td align="left" rowspan="1" colspan="1">17.69 (3.92)</td><td align="left" rowspan="1" colspan="1">18.00 (3.70)</td><td align="left" rowspan="1" colspan="1">17.56 (3.70)</td><td align="left" rowspan="1" colspan="1">17.36 (3.71)</td></tr><tr><td align="left" rowspan="1" colspan="1">Rivastigmine</td><td align="left" rowspan="1" colspan="1">17.13 (3.15)</td><td align="left" rowspan="1" colspan="1">16.86 (3.95)</td><td align="left" rowspan="1" colspan="1">17.19 (3.94)</td><td align="left" rowspan="1" colspan="1">17.46 (3.45)</td><td align="left" rowspan="1" colspan="1">17.24 (3.43)</td></tr><tr><td align="left" rowspan="1" colspan="1">MLC601</td><td align="left" rowspan="1" colspan="1">17.77 (1.69)</td><td align="left" rowspan="1" colspan="1">18.15 (2.65)</td><td align="left" rowspan="1" colspan="1">18.25 (2.50)</td><td align="left" rowspan="1" colspan="1">17.90 (2.33)</td><td align="left" rowspan="1" colspan="1">17.47 (2.21)</td></tr><tr><td align="left" rowspan="1" colspan="1">Galantamine</td><td align="left" rowspan="1" colspan="1">17.90 (1.92)</td><td align="left" rowspan="1" colspan="1">18.09 (2.87)</td><td align="left" rowspan="1" colspan="1">17.88 (3.13)</td><td align="left" rowspan="1" colspan="1">17.56 (3.02)</td><td align="left" rowspan="1" colspan="1">17.30 (3.09)</td></tr></tbody></table></table-wrap><table-wrap id="T7" orientation="portrait" position="float"><label>Table 7</label><caption><p>Means and standard deviations of ADAS-Cog scores in each group</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th align="left" rowspan="1" colspan="1">Group</th><th align="left" rowspan="1" colspan="1">Baseline</th><th align="left" rowspan="1" colspan="1">4th month</th><th align="left" rowspan="1" colspan="1">8th month</th><th align="left" rowspan="1" colspan="1">12th month</th><th align="left" rowspan="1" colspan="1">16th month</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Donepezil</td><td align="left" rowspan="1" colspan="1">27.80 (6.56)</td><td align="left" rowspan="1" colspan="1">28.10 (8.58)</td><td align="left" rowspan="1" colspan="1">27.48 (7.67)</td><td align="left" rowspan="1" colspan="1">28.27 (7.87)</td><td align="left" rowspan="1" colspan="1">28.87 (7.67)</td></tr><tr><td align="left" rowspan="1" colspan="1">Rivastigmine</td><td align="left" rowspan="1" colspan="1">29.69 (7.78)</td><td align="left" rowspan="1" colspan="1">30.12 (9.39)</td><td align="left" rowspan="1" colspan="1">29.42 (9.30)</td><td align="left" rowspan="1" colspan="1">28.62 (7.91)</td><td align="left" rowspan="1" colspan="1">29.37 (7.63)</td></tr><tr><td align="left" rowspan="1" colspan="1">MLC601</td><td align="left" rowspan="1" colspan="1">27.51 (4.19)</td><td align="left" rowspan="1" colspan="1">27.06 (6.52)</td><td align="left" rowspan="1" colspan="1">26.75 (5.96)</td><td align="left" rowspan="1" colspan="1">27.55 (6.15)</td><td align="left" rowspan="1" colspan="1">28.45 (6.04)</td></tr><tr><td align="left" rowspan="1" colspan="1">Galantamine</td><td align="left" rowspan="1" colspan="1">27.37 (5.02)</td><td align="left" rowspan="1" colspan="1">26.98 (6.45)</td><td align="left" rowspan="1" colspan="1">27.60 (7.48)</td><td align="left" rowspan="1" colspan="1">28.40 (7.36)</td><td align="left" rowspan="1" colspan="1">29.14 (7.65)</td></tr></tbody></table></table-wrap></floats-group></article>